Minerva Neurosciences Inc NERV

NAS: NERV | ISIN: US6033801068 30/04/2025

1,670 USD (-3,19%)

(-3,19%) 30/04/2025

Grafiek Minerva Neurosciences Inc

Grafiek Minerva Neurosciences Inc

1 dag1d -3,19%
1 week1w -4,57%
1 maand1m 7,75%
3 maanden3m -25,94%
6 maanden6m -36,26%
1 jaar1j -30,42%
5 jaar5j -82,22%

Minerva Neurosciences Inc in het nieuws

Toon enkel gratis nieuws

25 februari 2025 · Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates · Persbericht

5 november 2024 · Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates · Persbericht

6 augustus 2024 · Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates · Persbericht

1 mei 2024 · Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates · Persbericht

27 februari 2024 · Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia · Persbericht

22 februari 2024 · Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates · Persbericht

7 november 2023 · Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates · Persbericht

1 augustus 2023 · Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates · Persbericht

28 juni 2023 · Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market · Persbericht

15 mei 2023 · Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates · Persbericht

Profiel Minerva Neurosciences Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: minervaneurosciences.com

Hoofdzetel: Waltham, Massachusetts Verenigde Staten

CEO: Remy Luthringer

Werknemers: 8

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe